SCHEMBL2920158

SCHEMBL2920158

CC(C)(C)OC(=O)N1CCC(CS(=O)(=O)NC(=O)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.62

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
STS P08842 5/20 0.62
TGFBR1 P36897 3/20 0.51
KDM4E B2RXH2 1/20 0.47
PKM P14618 1/20 0.47
SCN9A Q15858 1/20 0.47
KCNH2 Q12809 1/20 0.45
CACNA1I Q9P0X4 1/20 0.45
GPR119 Q8TDV5 5/20 0.45
TACR1 P25103 1/20 0.44
SFRP1 Q8N474 1/20 0.44
RORC P51449 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27702431 0.84 KCNH2 (0.46) STSTGFBR1KCNH2CACNA1I
SCHEMBL7803789 0.83 KDM4E (0.69) STSTGFBR1KDM4EPKMKCNH2
SCHEMBL5627334 0.81 STS (0.49) STSTGFBR1KCNH2CACNA1ITACR1
SCHEMBL2921629 0.81 STS (0.53) STSTGFBR1GPR119TACR1
SCHEMBL17942537 0.78 TGFBR1 (0.59) STSTGFBR1KDM4EPKMGPR119
SCHEMBL7787125 0.78 STS (0.58) STSTGFBR1SCN9AGPR119RORC
SCHEMBL4131317 0.77 STS (0.56) STSTGFBR1SCN9AGPR119TACR1
SCHEMBL4146167 0.77 STS (0.54) STSTGFBR1KDM4EPKMGPR119
SCHEMBL2952898 0.77 STS (1.00) STSTGFBR1TACR1SFRP1
SCHEMBL2916404 0.76 STS (0.55) STSTGFBR1SCN9ATACR1SFRP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228364-A1 Acylsulfonamides as inhibitors of steroid sulfatase Novartis AG (CH) 2010-09-15 EP disclosed
US-20090227620-A1 ANTI-INFLAMMATORY COMPOUNDS MEINGASSNER JOSEF GOTTFRIED 2009-09-10 US disclosed
US-7482462-B2 Acylsulfonamides as inhibitors of steroid sulfatase NOVARTIS AG (CH) 2009-01-27 US disclosed
US-20080293758-A1 Combination of a Steroid Sulfatase Inhibitor and an Ascomycin NOVARTIS AG (CH) 2008-11-27 US disclosed
EP-1861098-A1 ANTI-INFLAMMATORY COMPOUNDS Novartis AG (CH) 2007-12-05 EP disclosed
EP-1861099-A2 COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN Novartis AG (CH) 2007-12-05 EP disclosed
WO-2006097293-A2 COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN NOVARTIS AG (CH) 2006-09-21 WO disclosed
WO-2006097292-A1 ANTI-INFLAMMATORY COMPOUNDS NOVARTIS AG (CH) 2006-09-21 WO disclosed
US-20050059712-A1 Acylsulfonamides as inhibitors of steroid sulfatase NOVARTIS AG (CH) 2005-03-17 US disclosed
EP-1436253-A1 ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE Novartis AG (CH) 2004-07-14 EP disclosed
WO-2003031397-A1 ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE NOVARTIS AG (CH) 2003-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293758-A1 Combination of a Steroid Sulfatase Inhibitor and an Ascomycin STS, ARSA, CYP17A1 STS 1/4885TGFBR1 4342/4885KDM4E 3548/4885
US-20090227620-A1 ANTI-INFLAMMATORY COMPOUNDS STS, SERPINB1, MPO STS 1/4885TGFBR1 4038/4885KDM4E 3346/4885
US-20050059712-A1 Acylsulfonamides as inhibitors of steroid sulfatase STS, SULT2A1, ARSA STS 1/4885TGFBR1 2802/4885KDM4E 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.